PHGE BiomX Inc.

NYSE biomx.com


$ 0.38 $ 0.00 (0 %)    

Thursday, 13-Nov-2025 09:34:56 EST
QQQ $ 614.92 $ -2.63 (-0.43 %)
DIA $ 481.83 $ 0.47 (0.1 %)
SPY $ 679.14 $ -1.40 (-0.21 %)
TLT $ 89.86 $ 0.05 (0.06 %)
GLD $ 387.91 $ 0.62 (0.16 %)
$ 0.3763
$ 0.38
$ 0.38 x 100
$ 0.38 x 100
$ 0.38 - $ 0.38
$ 0.34 - $ 1.16
1,271,930
na
nm
$ 1.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-25-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-20-2024 03-31-2024 10-Q
8 04-04-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-29-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-30-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-24-2021 03-31-2021 10-Q
20 03-31-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-26-2020 12-31-2019 10-K
25 10-16-2019 09-30-2019 10-Q
26 08-21-2019 06-30-2019 10-K
27 05-10-2019 03-31-2019 10-Q
28 02-06-2019 12-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 correction-biomx-q3-eps-029-beats-032-estimate-cash--equivalents-81m

BiomX (AMEX:PHGE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.32) by 9.38 p...

 earnings-preview-for-biomx
Earnings Preview For BiomX
11/11/2025 17:12:50

 biomx-receives-fda-support-to-advance-bx011-phage-therapy-for-diabetic-foot-infections

BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and enginee...

 biomx-releases-update-for-the-fda-clinical-hold-for-us-portion-of-its-bx004-phase-2b-cystic-fibrosis-trial-receiving-written-feedback-from-fda-suggesting-potential-development-strategies-for-bx004-including-ways-to-enrich-study-populations-for-phase-3-development

BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and enginee...

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their ...

 hc-wainwright--co-reiterates-buy-on-biomx-maintains-15-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BiomX (AMEX:PHGE) with a Buy and maintains $15 price target.

 biomx-says-fda-places-clinical-hold-on-phase-2b-trial-of-bx004-for-treatment-of-patients-with-cystic-fibrosis

U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used t...

 biomx-q2-eps-019-beats-033-estimate-cash-cash-equivalents-and-restricted-cash-of-152m-are-sufficient-to-fund-its-operations-into-q1-of-2026

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patient...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION